Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Non-Current Deffered Revenue (2019 - 2026)

Enliven Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $217000.0 for Q1 2026.

  • Quarterly results put Non-Current Deffered Revenue at $217000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was $217000.0 (changed N/A YoY), and the annual figure for FY2025 was $217000.0, changed.
  • Non-Current Deffered Revenue reached $217000.0 in Q1 2026 per ELVN's latest filing, roughly flat from $217000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $4.0 million in Q4 2022 and bottomed at $217000.0 in Q3 2025.
  • Median Non-Current Deffered Revenue over the past 5 years was $563000.0 (2023), compared with a mean of $796500.0.
  • The largest annual shift saw Non-Current Deffered Revenue crashed 85.84% in 2023 before it grew 7.44% in 2024.
  • Over 5 years, Non-Current Deffered Revenue stood at $4.0 million in 2022, then plummeted by 85.84% to $563000.0 in 2023, then changed by 0.0% to $563000.0 in 2024, then plummeted by 61.46% to $217000.0 in 2025, then changed by 0.0% to $217000.0 in 2026.
  • Business Quant data shows Non-Current Deffered Revenue for ELVN at $217000.0 in Q1 2026, $217000.0 in Q4 2025, and $217000.0 in Q3 2025.